Cs4 for Pneumoconiosis Rehabilitation
Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract (Cs4) Supplementation in Pneumoconiosis Rehabilitation: a Randomized, Controlled Trial
This clinical trial will test whether a Cordyceps supplement improves lung function. The supplement is called Cordyceps sinensis mycelium Culture extract (Cs4). The study will include adults with pneumoconiosis, a lung disease caused by breathing in mineral dust. Researchers will also assess Cs4 safety.
The main questions are: (1) does Cs4 improve lung function compared with a placebo? (2) what health problems occur while participants take Cs4?
The study will include 84 adults aged 18 to 75 years. Their breathing condition must have been stable for at least three months. The study will take place at the School of Chinese Medicine, The University of Hong Kong.
Researchers will compare Cs4 with a placebo, a look-alike capsule containing no Cs4. Chance will determine which capsules each participant receives. Each participant has an equal chance of joining either group. Participants and researchers who assess them will not know which capsules participants receive.
Participants will: (1) take two capsules of Cs4 or placebo twice daily for 24 weeks; (2) record the capsules they take each day and return unused capsules at study visits; (3) attend clinic visits for breathing tests, a walking test, and blood tests; (4)answer questions about their breathing symptoms and daily life. (5) continue follow-up visits for 12 weeks after finishing the capsules.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Tung Leong Fong
- Puhelinnumero: +852 5660 4020
- Sähköposti: u3557512@connect.hku.hk
Tutki yhteystietojen varmuuskopiointi
- Nimi: Yunqing Xun
- Puhelinnumero: +852 5229 5427
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria: (1) adults aged 18-75 years; (2) diagnosed with pneumoconiosis based on clinical and radiological criteria, including chest X-ray/computed tomography and International Labour Organization (ILO) classification; (3)stable respiratory condition for at least 3 months before enrollment, with no acute exacerbations, hospitalizations, or changes in respiratory medication; (4)able to provide written informed consent.
Exclusion Criteria:
(1) history of chronic respiratory diseases other than pneumoconiosis that may confound FEV1/FVC assessment, such as asthma, bronchiectasis, or interstitial lung disease of other etiologies; (2) known allergy to Cordyceps sinensis or any component of the study supplement; (3) pregnancy or breastfeeding; (4)severe comorbid conditions that could interfere with participation, such as active cancer, decompensated heart failure classified as New York Heart Association (NYHA) Class III-IV, or uncontrolled psychiatric illness; (5) cognitive impairment affecting decision-making capacity.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Tukevaa hoitoa
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kolminkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Cs4 supplementation
Participants will receive Cordyceps sinensis mycelium culture extract (Cs4) orally at 1.6 g per day, administered as two 0.4 g capsules twice daily for 24 weeks, followed by 12 weeks of follow-up. |
Cordyceps sinensis Mycelium Culture Extract (Cs4) is a fermented mycelial preparation of Cordyceps sinensis, a fungus used in Traditional Chinese Medicine. It is produced by cultivating and fermenting the mycelium, the vegetative part of the fungus. In this trial, Cs4 is used as a dietary supplement to investigate its effects on lung function and rehabilitation outcomes in adults with pneumoconiosis. |
|
Placebo Comparator: Matching placebo
Participants will receive matching placebo orally, administered as two capsules twice daily for 24 weeks, followed by 12 weeks of follow-up. Placebo capsules will contain starch, sucrose, and food-grade colorants and will match Cs4 capsules in size, color, weight, smell, and packaging. |
Matching placebo capsules containing starch, sucrose, and food-grade colorants, with no Cs4 extract. The placebo capsules will match the Cs4 capsules in size, color, weight, and smell and will be supplied in identical blister packs to maintain blinding. Participants will take two capsules orally twice daily for 24 weeks. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Forced Expiratory Volume in One Second/ Forced Vital Capacity (FEV1/FVC) ratio
Aikaikkuna: from baseline to week 24
|
Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) will be measured by trained, blinded assessors using standardized spirometry according to American Thoracic Society/European Respiratory Society standards. |
from baseline to week 24
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Forced Expiratory Volume in One Second (FEV1)
Aikaikkuna: Baseline, week 12, week 24, and week 36
|
Change from baseline in FEV1, measured in liters by spirometry according to American Thoracic Society/European Respiratory Society standards. |
Baseline, week 12, week 24, and week 36
|
|
Forced Vital Capacity (FVC)
Aikaikkuna: Baseline, week 12, week 24, and week 36
|
Change from baseline in FVC, measured in liters by spirometry according to American Thoracic Society/European Respiratory Society standards. |
Baseline, week 12, week 24, and week 36
|
|
Six-Minute Walk Distance (6MWD)
Aikaikkuna: Baseline, week 12, week 24, and week 36
|
Change from baseline in the total distance walked during the six-minute walk test, measured in meters. A longer distance indicates greater functional exercise capacity. |
Baseline, week 12, week 24, and week 36
|
|
St. George's Respiratory Questionnaire (SGRQ) Total Score
Aikaikkuna: Baseline, week 12, week 24, and week 36
|
Change from baseline in SGRQ total score, assessing overall impairment in respiratory health status. Scores range from 0 to 100, with higher scores indicating worse health status. |
Baseline, week 12, week 24, and week 36
|
|
Modified Medical Research Council (mMRC) Dyspnea Scale Score
Aikaikkuna: Baseline, week 12, week 24, and week 36
|
Change from baseline in mMRC Dyspnea Scale score, assessing limitations in daily activities caused by breathlessness. Scores range from 0 to 4, with higher scores indicating greater limitation. |
Baseline, week 12, week 24, and week 36
|
|
Leicester Cough Questionnaire (LCQ) Total Score
Aikaikkuna: Baseline, week 12, week 24, and week 36
|
Change from baseline in LCQ total score, assessing cough-related quality of life using 19 items across physical, psychological, and social domains. The total score ranges from 3 to 21, with higher scores indicating better quality of life. |
Baseline, week 12, week 24, and week 36
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
High-Sensitivity C-Reactive Protein (hs-CRP) Level
Aikaikkuna: Baseline, week 24, and week 36
|
Change from baseline in blood high-sensitivity C-reactive protein (hs-CRP) concentration, measured using an immunoturbidimetric assay. Change will be calculated separately at week 24 and week 36 by subtracting the baseline concentration from the concentration at each follow-up visit. |
Baseline, week 24, and week 36
|
|
Interleukin-6 (IL-6) Level
Aikaikkuna: Baseline, week 24, and week 36
|
Change from baseline in blood IL-6 concentration, measured using a high-sensitivity enzyme-linked immunosorbent assay (ELISA). Change will be calculated separately at week 24 and week 36 by subtracting the baseline concentration from the concentration at each follow-up visit. |
Baseline, week 24, and week 36
|
|
Malondialdehyde (MDA) Level
Aikaikkuna: Baseline, week 24, and week 36
|
Change from baseline in blood MDA level, assessed using a thiobarbituric acid reactive substances (TBARS) assay. Change will be calculated separately at week 24 and week 36 by subtracting the baseline value from the value at each follow-up visit. |
Baseline, week 24, and week 36
|
|
Superoxide Dismutase (SOD) Activity
Aikaikkuna: Baseline, week 24, and week 36
|
Change from baseline in blood SOD activity, measured using a colorimetric assay based on nitroblue tetrazolium reduction. Change will be calculated separately at week 24 and week 36 by subtracting the baseline activity from the activity at each follow-up visit. |
Baseline, week 24, and week 36
|
|
Glutathione Peroxidase (GPx) Activity
Aikaikkuna: Baseline, week 24, and week 36
|
Change from baseline in blood GPx activity, measured using a coupled enzyme assay based on nicotinamide adenine dinucleotide phosphate (NADPH) oxidation. Change will be calculated separately at week 24 and week 36 by subtracting the baseline activity from the activity at each follow-up visit. |
Baseline, week 24, and week 36
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- UW 26-315
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
De-identified individual participant data underlying the results reported in the primary study publication will be shared, together with a data dictionary. Shared data will include participant characteristics, treatment allocation, lung function measurements, six-minute walk distance, questionnaire scores, biomarker results, and adverse event data used in the published analyses. Direct identifiers and the participant identification linkage file will not be shared. Access will be provided to qualified researchers following approval of a research proposal and execution of a data use agreement. Sharing will be subject to any required institutional review board (IRB) and institutional approvals and must be consistent with participant consent.
IPD-jaon aikakehys
De-identified individual participant data and the selected supporting documents will be available from publication of the primary study results until five years after study completion.
IPD-jaon käyttöoikeuskriteerit
De-identified individual participant data underlying the published results, the data dictionary, and the selected supporting documents will be available to qualified researchers upon reasonable request. Requests should be submitted by email to the principal investigator and include a methodologically sound research proposal and statistical analysis plan. The principal investigator will review requests for scientific merit, feasibility, and consistency with participant consent and institutional requirements. Approved researchers may use the data only for analyses specified in the approved proposal. Access will require a signed data use agreement and any necessary IRB and institutional approvals. Data will be provided through secure transfer.
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- ANALYTIC_CODE
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .